Sancy A. Leachman, MD, PhD

Research Interests

  • Familial Melanoma
  • Melanoma
  • Vitiligo, Pigmentary Disorders


Lab Website


  • English

Academic Information

  • Departments: Dermatology - Adjunct Professor
  • Cancer Center Programs: Cancer Control & Population Sciences

Board Certification

  • American Board of Dermatology

Academic Office Information

  • 801-585-1810
  • Huntsman Cancer Institute
    2000 Circle of Hope, Room: 5242
    Salt Lake City, UT 84112

Academic Bio

Sancy Leachman, MD, PhD, is an adjunct Professor in the Department of Dermatology at the University of Utah School of Medicine and a member of the Cancer Control and Population Sciences Program. She is a dermatologist using basic science research and state-of-the-art technology to combat skin cancer. Her clinical interests include skin cancers, especially melanoma, pigmentary disorders that result from abnormalities of melanocytes such as vitiligo, and genetic disorders that involve the skin such as pachyonychia congenita, Cowden syndrome, and other cutaneous cancer syndromes.

Dr. Leachman examines the role of genetic predisposition and differential gene expression in the development of melanoma, with an emphasis on the familial melanoma syndrome. Through her investigations, she hopes to develop agents that will serve as diagnostic tools, prognostic indicators, or targeted agents for the prevention of melanoma.

Dr. Leachman was a key figure in developing the multidisciplinary Melanoma and Cutaneous Oncology group at Huntsman Cancer Institute. The program brings together researchers and physicians with an interest in melanoma and other skin cancers in order to bring knowledge and expertise from the laboratory into the clinical realm. By applying the latest scientific technology to the problem of human cancer, Dr. Leachman and her colleagues strive to improve the medical community's ability to diagnose and treat skin cancers. She was awarded the prestigious Doris Duke Clinical Scientist Development Award in 2000 and is currently an NIH R01- and DoD-funded principle investigator.

Education History

Type School Degree
Fellowship Yale University School of Medicine
Cutaneous Oncology
Residency Yale - New Haven Hospital
Internship University of Texas Southwestern Medical School
Internal Medicine
Professional Medical University of Texas
M.D., Ph.D.
Undergraduate University of Texas at Austin Plan II
Liberal Arts

Selected Publications

Journal Article

  1. Curiel-Lewandrowski C, Kim CC, Swetter SM, Chen SC, Halpern AC, Kirkwood JM, Leachman SA, Marghoob AA, Ming ME, Grichnik JM (2012). Survival is not the only valuable end point in melanoma screening. J Invest Dermatol, 132(5), 1332-7.
  2. Teerlink C, Farnham J, Allen-Brady K, Camp NJ, Thomas A, Leachman S, Cannon-Albright L (2012). A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum Genet, 131(1), 77-85.
  3. Sondak VK, Leachman SA (2011). Individualizing follow-up for patients with early-stage melanoma. J Clin Oncol, 29(35), 4606-8.
  4. Moos PJ, Olszewski K, Honeggar M, Cassidy P, Leachman S, Woessner D, Cutler NS, Veranth JM (2011). Responses of human cells to ZnO nanoparticles: a gene transcription study. Metallomics, 3(11), 1199-211.
  5. Jenkins NC, Liu T, Cassidy P, Leachman SA, Boucher KM, Goodson AG, Samadashwily G, Grossman D (2011). The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene, 30(3), 265-74.
  6. Leaf SL, Aspinwall LG, Leachman SA (2010). God and Agency in the Era of Molecular Medicine: Religious Beliefs Predict Sun-Protection Behaviors Following Melanoma Genetic Test Reporting. Archive for the Psychology of Religion (English), 32, 1-26.
  7. Kadekaro AL, Leachman S, Kavanagh RJ, Swope V, Cassidy P, Supp D, Sartor M, Schwemberger S, Babcock G, Wakamatsu K, Ito S, Koshoffer A, Boissy RE, Manga P, Sturm RA, Abdel-Malek ZA (2010). Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J, 24(10), 3850-60.
  8. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6.
  9. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarra G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, Grant-Kels J, Halpern AC, Ingvar C, Kefford RF, Lang J, MacKie RM, Mann GJ, Mueller K, Newton-Bishop J, Olsson H, Petersen GM, Puig S, Rigel D, Swetter SM, Tucker MA, Yakobson E, Zitelli JA, Tsao H (2009). Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol, 61(4), 677.e1-14.
  10. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, Wiggins C, Noyes RD, Tsodikov A, Cannon-Albright LA, Zone JJ, Samlowski WE, Leachman SA (2005). Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol, 23(28), 7168-77.